Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Frontiers in Oncology|October 26, 2020
Overcoming Limitations of Cisplatin Therapy by Additional Treatment With the HSP90 Inhibitor OnalespibAnja Charlotte Lundgren Mortensen, Tabassom Mohajershojai, Mehran Hariri, et al.
Frontiers in Oncology|May 28, 2026
Correction: Overcoming limitations of cisplatin therapy by additional treatment with the HSP90 inhibitor onalespibAnja Charlotte Lundgren Mortensen, Tabassom Mohajershojai, Mehran Hariri, et al.
Frontiers in Oncology|October 17, 2019
The Stapled Peptide PM2 Stabilizes p53 Levels and Radiosensitizes Wild-Type p53 Cancer CellsAnja Charlotte Lundgren Mortensen, Diana Spiegelberg, Christopher John Brown, et al.
Scientific Reports|October 6, 2023
Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancerAnja Charlotte Lundgren Mortensen, Hanna Berglund, Mehran Hariri, et al.
Scientific Reports|April 5, 2020
The HSP90 inhibitor Onalespib exerts synergistic anti-cancer effects when combined with radiotherapy: an in vitro and in vivo approachDiana Spiegelberg, Andris Abramenkovs, Anja Charlotte Lundgren Mortensen, et al.
Nuclear Medicine and Biology|April 20, 2025
Affinity maturation and optimization of CD44v6-targeting antibodies for molecular radiotherapyAnja Charlotte Lundgren Mortensen, Camilla Hofström, Helena Persson, et al.
Frontiers in Oncology|October 5, 2020
The Novel Anti-cMet Antibody seeMet 12 Potentiates Sorafenib Therapy and Radiotherapy in a Colorectal Cancer ModelDiana Spiegelberg, Anja Charlotte Lundgren Mortensen, Kartika Dyah Palupi, et al.
Molecular Cancer Therapeutics|February 20, 2025
Dual-Nuclide Biodistribution and Therapeutic Evaluation of a Novel Antibody-Based Radiopharmaceutical in Anaplastic Thyroid Cancer XenograftsAnja Charlotte Lundgren Mortensen, Hanna Berglund, Preeti Jha, et al.
Pageof 1